Predicted Trait | |
Reported Trait | Hepatic fat content |
Mapped Trait(s) | liver fat measurement (EFO_0010821) |
Score Construction | |
PGS Name | PRS-HFC_SOS |
Development Method | |
Name | Variants with validated effects on hepatic fat accumulation and/or nonalcoholic fatty liver disease severity and with experimental data supporting the casuality of the association |
Parameters | NR |
Variants | |
Original Genome Build | NR |
Number of Variants | 4 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000212 |
Citation (link to publication) | Dongiovanni P et al. J Intern Med (2017) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
Europe PMC: 18820647 |
1,032 individuals | African American or Afro-Caribbean | DaHS |
Europe PMC: 18820647 |
696 individuals | European | DaHS |
Europe PMC: 18820647 |
383 individuals | Hispanic or Latin American | DaHS |
GWAS Catalog: GCST001008 Europe PMC: 21423719 |
7,176 individuals | European | AGES, AMISH, FHS, FamHS |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
2,448 individuals | African American or Afro-Caribbean | DaHS |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
1,365 individuals | European | DaHS |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
753 individuals | Hispanic or Latin American | DaHS |
GWAS Catalog: GCST003153 Europe PMC: 26482880 |
2,138 individuals | European | NR |
GWAS Catalog: GCST001928 Europe PMC: 23535911 |
1,326 individuals | East Asian | NR |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
141 individuals | Not reported | DaHS |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
— | 631 individuals | European | LiverBC | All individuals were identified as being morbidly obese, defined by the presence of a body mass index ≥ 40 kg m−2 or ≥35 kg m−2 in patients with metabolic comorbidities (type 2 diabetes, dyslipidemia or arterial hypertension). | — | — | — | — |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM002410 | PSS001090| European Ancestry| 3,329 individuals |
PGP000212 | Dongiovanni P et al. J Intern Med (2017) |
Reported Trait: Alanine aminotransferase levels | — | — | Association p-value (<): 1.00e-14 | Age, sex, ethnicity, body mass index, statin use | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS001090 | All individuals were identified as being severly obese. Homeostasis model assessment-insulin resistance index was calculated from fasting levels of glucose and insulin. Plasma levels of lipids and lipoproteins were measured by standard enzymatic assays. | — | 3,329 individuals, 30.0 % Male samples |
Mean = 48.0 years Sd = 6.0 years |
European | — | SOS | — |